文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑转移速度(BMV)的多机构外部验证:立体定向放疗后结局的新型预测指标

Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery.
PubMed 文献 · Radiother Oncol · 2019-09-13

本研究在九家学术中心中纳入2829例接受 upfront SRS 的患者,其中八家机构未参与BMV定义,最终2092例进入验证集,921例(44.0%)发生远处脑失败(DBF)。按BMV分层,<4、4–13、>13组的初始SRS后中位OS分别为12.5、7.0、4.6个月(p<0.0001);多因素回归显示黑色素瘤组织学与初始脑转移数目仍可预测BMV,验证了BMV对OS的预后价值,并已作为挽救全脑放疗对比挽救SRS随机试验的分层变量。

要点

  • BMV<4、4–13、>13组中位OS分别为12.5、7.0、4.6个月(p<0.0001)。
  • 验证集2092例中921例(44.0%)发生远处脑失败。
  • 黑色素瘤组织学与初始脑转移数目仍可预测BMV。

核心结论

  • 多机构数据验证BMV可作为初始SRS后总生存的预测指标。

研究设计与样本

  • 多机构外部验证研究,九家学术中心接受 upfront SRS 的患者中,八家未参与BMV定义的机构数据构成验证集。
  • 验证集共2092例患者,按BMV分为低危(<4)、中危(4–13)、高危(>13)三组。

主要发现

  • 验证集2092例中921例(44.0%)发生远处脑失败(DBF)。
  • 初始SRS后中位OS为11.2个月。
  • BMV<4、4–13、>13组中位OS分别为12.5、7.0、4.6个月(p<0.0001)。
  • 多因素回归中黑色素瘤组织学(β:10.10,SE:1.89,p<0.0001)与初始脑转移数目(β:1.52,SE:0.34,p<0.0001)仍可预测BMV(调整R2=0.06)。

关键数值与推荐

  • BMV分组界值:低危<4、中危4–13、高危>13。

临床怎么用

  • BMV可用于初始SRS后患者的风险分层与预后判断。
  • BMV已被即将开展的多机构随机对照试验用作DBF后挽救全脑放疗对比挽救SRS的分层变量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Brain metastasis velocity (BMV) is a prognostic metric that describes the recurrence rate of new brain metastases after initial treatment with radiosurgery (SRS). We have previously risk stratified patients into high, intermediate, and low-risk BMV groups, which correlates with overall survival (OS). We sought to externally validate BMV in a multi-institutional setting. METHODS: Patients from nine academic centers were treated with upfront SRS; the validation cohort consisted of data from eight institutions not previously used to define BMV. Patients were classified by BMV into low (<4 BMV), intermediate (4-13 BMV), and high-risk groups (>13 BMV). Time-to-event outcomes were estimated using the Kaplan-Meier method. Cox proportional hazards methods were used to estimate the effect of BMV and salvage modality on OS. RESULTS: Of 2829 patients, 2092 patients were included in the validation dataset. Of these, 921 (44.0%) experienced distant brain failure (DBF). Median OS from initial SRS was 11.2 mo. Median OS for BMV < 4, BMV 4-13, and BMV > 13 were 12.5 mo, 7.0 mo, and 4.6 mo (p < 0.0001). After multivariate regression modeling, melanoma histology (β: 10.10, SE: 1.89, p < 0.0001) and number of initial brain metastases (β: 1.52, SE: 0.34, p < 0.0001) remained predictive of BMV (adjusted R2 = 0.06). CONCLUSIONS: This multi-institutional dataset validates BMV as a predictor of OS following initial SRS. BMV is being utilized in upcoming multi-institutional randomized controlled trials as a stratification variable for salvage whole brain radiation versus salvage SRS after DBF.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. McTyre ER, Soike MH, Farris M, et al. Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiother Oncol. 2019. PMID: 31526671. doi:10.1016/j.radonc.2019.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。